ClinicalTrials.gg
CompletedNCT05145608Updated Dec 7, 2021

Comparative Bioavailability Study of Lamotrigine ER Tablets USP 50 mg

A Phase 1 interventional study of Lamotrigine ER tablet 50mg in Bioequivalence, sponsored by Alembic Pharmaceuticals Ltd.. Completed at 1 site in Canada. Open to participants aged 18 Years to 54 Years, including healthy volunteers. Per ClinicalTrials.gov, last updated 2021-12-07.

Sponsored by Alembic Pharmaceuticals Ltd. · Phase 1, Interventional, and Other

From the registry’s dates

  • Primary completion was Feb 2018, 8 years 8 months ago, and no results have been posted to the registry.

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 1
Study type
Interventional
Enrollment
22
Allocation
Randomized
Ages
18 Years to 54 Years
Sex
All
01

Study summary

Objective:

To evaluate and compare the bioavailability and therefore to assess the bioequivalence of two different formulations of lamotrigine after a single oral dose administration under fasting conditions.

The secondary objective is to monitor the safety of the subjects.

Read the detailed description

Study Design:

Single center, randomized, single dose, laboratory-blinded, 2-period, 2-sequence, crossover design

Subjects:

Twenty-two (22) subjects will be included in the study.

Main Inclusion Criteria:

Male and female volunteers, non- or ex-smokers, of at least 18 years of age to 54 years of age, inclusively, with a body mass index (BMI) within 22.00 to 30.00 kg/m2, inclusively, with a minimum body weight of 60 kg, will be selected according to the inclusion and exclusion criteria.

Blood Sampling:

In each study period, 23 blood samples will be collected. The first blood sample will be collected prior to drug administration while the others will be collected up to 192 hours after the drug administration.

Wash-out:

The drug administrations will be separated by at least 28 calendar days.

Tests during study:

An alcohol breath test will be performed before each period of the study. Screening for drugs of abuse will be performed before each period of the study. A C-SSRS questionnaire will be performed prior to each study period, as well as prior to discharge for each period of the study.

For female subjects, a serum pregnancy test will be performed before each period of the study.

Vital signs will be measured prior to and approximately 2, 4, 8, 10, 12, 24, 36 and 48 hours following each drug administration.

Neurological function tests will be performed approximately 30 hours after each drug administration.

For safety reasons, hematology tests will be performed before the 2nd period of the study.

Post study Tests:

Hematology, general biochemistry (including a serum pregnancy test for female subjects), and urinalysis tests will be repeated along with the collection of the last blood sample of the study.

A complete physical examination (including vital signs) will also be performed.

Bioanalysis: Lamotrigine plasma concentrations will be measured by a validated bioanalytical method.

02

Conditions studied

  • Bioequivalence
03

In context

Lead sponsor

Alembic Pharmaceuticals Ltd. is the lead sponsor of 3 studies on the registry; none are open to participants now.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
18 Years to 54 Years
Sexes eligible
All
Accepts healthy volunteers
Yes

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  1. Availability for the entire study period
  2. Motivated volunteer and absence of intellectual problems likely to limit the validity of consent to participate in the study or the compliance with protocol requirements; ability to cooperate adequately; ability to understand and observe the instructions of the physician or designee
  3. Male or female volunteer
  4. A female volunteer must meet one of the following criteria:

    1. Participant is of and agrees to use one of the accepted regimens from at least 28 days prior to the first administration of the study drug, during the study and for at least 30 days after the last dose of the study drug. An acceptable method of contraception includes one of the following:

      • Abstinence from heterosexual intercourse
      • Intrauterine device (without hormones)
      • Condom with intra-vaginally applied spermicide or
    2. Participant is of non-childbearing potential, defined as surgically sterile (i.e. has undergone complete hysterectomy, bilateral oophorectomy, or tubal ligation) or in a menopausal state (at least 1 year without menses)
  5. Volunteer aged of at least 18 years to 54 years of age, inclusively
  6. Volunteer with a within 22.00 to 30.00 kg/m2, inclusively
  7. Minimum body weight of 60 kg
  8. Non- or ex-smokers; an ex-smoker being defined as someone who completely stopped smoking for at least 6 months before day 1 of this study
  9. Clinical laboratory values within the laboratory's stated normal range; if not within this range, must be without any clinical significance
  10. Have no diseases captured in the medical history or evidence of clinically significant findings on physical examination and/or clinical laboratory evaluations (hematology, general biochemistry, and urinalysis)
  11. Willingness to adhere to the protocol requirements as evidenced by the form (ICF) duly read, signed and dated by the volunteer The informed consent form must be signed by all volunteers prior to their participation in the study.

Exclusion criteria

Exclusion Criteria:

  1. Difficulty donating blood
  2. History of difficulty in swallowing or of any gastrointestinal disease which could affect drug absorption
  3. Volunteer who is associated to Algorithme Pharma (staff member or immediate family of a staff member)
  4. Females who are pregnant or are lactating
  5. History of significant to lamotrigine or any related products (including of the formulations) as well as severe hypersensitivity reactions (like angioedema) to any drugs
  6. History of any prior allergic drug rash
  7. Presence of significant gastrointestinal, liver or kidney disease, or any other conditions known to interfere with the absorption, distribution, metabolism or excretion of drugs or known to potentiate or predispose to undesired effects
  8. History of significant gastrointestinal, liver or kidney disease that may affect drug bioavailability
  9. Presence of significant cardiovascular, pulmonary, hematologic, neurological, psychiatric, endocrine, immunologic or dermatologic disease
  10. Showing suicidal tendency as per the Columbia Suicide Severity Rating Scale (C-SSRS) administered at screening
  11. Presence of out-of-range cardiac interval (PR \< 110 msec, PR > 220 msec, QRS \< 60 msec, QRS >119 msec and > 450 msec for males and > 460 msec for females) on the screening or other ECG abnormalities
  12. Known presence of rare hereditary problems of galactose and /or lactose intolerance, lactase deficiency or glucose-galactose malabsorption
  13. Maintenance therapy with any drug or significant history of drug dependency or alcohol abuse (> 3 units of alcohol per day, intake of excessive alcohol, acute or chronic)
  14. Any clinically significant illness in the previous 28 days before day 1 of this study
  15. Use of any enzyme-modifying drugs, including strong inhibitors of cytochrome P450 (CYP) enzymes (such as cimetidine, fluoxetine, quinidine, erythromycin, ciprofloxacin, fluconazole, ketoconazole, diltiazem and antivirals) and strong inducers of CYP enzymes (such as barbiturates, carbamazepine, , phenytoin, rifampin and St John's Wort), in the previous 28 days before day 1 of this study
  16. Any history of tuberculosis and/or prophylaxis for tuberculosis
  17. Positive screening of alcohol and/or drugs of abuse
  18. Positive results to HIV Ag/Ab Combo, surface Antigen (HBsAG (B) (hepatitis B)) or Virus (HCV (C)) tests
  19. Females who are pregnant according to a positive serum pregnancy test
  20. Volunteers who took an Product (in another clinical trial) in the previous 28 days before day 1 of this study
  21. Volunteers who took an Investigational Product (in another clinical trial) with a long half-life (≥120 hours) in the previous 3 months before day 1 of this study
  22. Volunteers who took lamotrigine in the previous 28 days before day 1 of this study
  23. Females who use the following systemic : oral, patch or vaginal ring, in the 28 days before day 1 of this study
  24. Females who use hormone replacement therapy in the 28 days before day 1 of this study
  25. Females who use the following systemic contraceptives: injections or implant, or hormone-releasing intrauterine device in the previous 13 weeks before day 1 of this study
  26. Volunteers who donated 50 mL or more of blood in the previous 28 days before day 1 of this study
  27. Donation of 500 mL or more of blood (Canadian Blood Services, Hema-Quebec, clinical studies, etc.) in the previous 56 days before day 1 of this study
Terms in these criteria, in plain language(14)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Childbearing potential

Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).

Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

BMI (body mass index)

Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.

What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.

Clinically significant

Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.

ECG (electrocardiogram)

A recording of the heart’s electrical activity, taken with stickers on the chest, arms and legs. It takes a few minutes and does not hurt.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Hypersensitivity

An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.

Excipients

The other ingredients in a medicine besides the active drug, such as fillers, colors or preservatives.

QT and QTc

On an ECG, the QT interval is the time the heart’s lower chambers take to activate electrically and recover in each beat. QTc is that time adjusted for heart rate (QTcF by Fridericia’s formula, QTcB by Bazett’s). Some medicines lengthen it, and a long QTc can raise the risk of a dangerous heart rhythm.

The study may name a correction formula and a limit in milliseconds, often around 450–480.

HIV

The human immunodeficiency virus, which weakens the immune system.

Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.

Corticosteroids (steroids)

Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.

Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.

Hepatitis B tests

Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.

Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.

Hepatitis C tests

Hepatitis C is a virus that infects the liver. An HCV antibody test can stay positive after an infection has cleared (and is occasionally positive without one); an HCV RNA test shows whether the virus is there now.

After treatment, hepatitis C counts as cured when HCV RNA is still undetectable 12 weeks or more after the treatment ended. Studies often accept people cured this way.

Investigational drug or device

A drug or device being studied in a clinical trial.

It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.

05

Study design

Phase
Phase 1
Primary purpose
Other
Allocation
Randomized
Intervention model
Crossover assignment
Masking
None (open label)
Enrollment
22 participants (actual)

Study arms

  • Active comparator
    Test- Lamotrigine ER Tablets USP 50mg

    Single dose of Test- Lamotrigine ER Tablets USP 50mg will be administered

    Drug: Lamotrigine ER tablet 50mg

  • Active comparator
    Reference- Lamictal® XRTM ER tablet 50mg

    Single dose of Reference- Lamictal® XRTM (Lamotrigine) ER tablet 50mg will be administered

    Drug: Lamotrigine ER tablet 50mg

Interventions

  • In each study period, a single 50 mg dose of lamotrigine will be administered orally with about 240 mL of water at ambient temperature, in the morning, while subjects are seated, following a 10-hour overnight fast.

    Also known as: Reference- Lamictal® XRTM (Lamotrigine) ER tablet 50mg

06

What researchers measure

Primary outcomes

  1. Cmax

    Peak Plasma Concentration (Cmax)

    Time frame: Up to 192 hours

  2. AUC0-T

    Area under the plasma concentration versus time curve (AUC)

    Time frame: Up to 192 hours

  3. AUC0-∞

    Area under the plasma concentration versus time curve (AUC)

    Time frame: Up to 192 hours

07

Study locations

1 site
  • Algorithme Pharma
    Mount Royal, Quebec H3P 3P1, Canada
08

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reached

Ran from Jan 2018 to primary completion in Feb 2018, 1 month.

How these figures are worked out, and which studies are left out of them.

Registered
Jan 9, 2018
First posted
Dec 6, 2021
StartActual
Jan 10, 2018
Primary completionActual
Feb 21, 2018
CompletionActual
Feb 21, 2018
Last update
Dec 7, 2021
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Dec 7, 2021, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
09

Registry details

Key details

Study ID
NCT05145608
Lead sponsor
Alembic Pharmaceuticals Ltd.
Responsible party
Sponsor
First posted
Dec 6, 2021
Start date
Jan 10, 2018
Primary completion
Feb 21, 2018
Completion
Feb 21, 2018
Last update
Dec 7, 2021

Study contacts

Eric Sicard, MD
principal investigator · Algorithme Pharma Inc

Oversight

Data monitoring committee
No
FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Dec 2021. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Lamotrigine

Start the discussion